Biomea Fusion, Inc. (BMEA)
NASDAQ
Market Cap
$155.83M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
273 of 950
Rank in Industry
165 of 543
Largest Insider Buys in Sector
BMEA Stock Price History Chart
BMEA Stock Performance
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Insider Activity of Biomea Fusion, Inc.
Over the last 12 months, insiders at Biomea Fusion, Inc. have bought $155,961 and sold $0 worth of Biomea Fusion, Inc. stock.
On average, over the past 5 years, insiders at Biomea Fusion, Inc. have bought $8.28M and sold $13.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hitchcock Michael J.M. (director) — $100,600. Valle Franco (Chief Financial Officer) — $55,361.
The last purchase of 10,000 shares for transaction amount of $100,600 was made by Hitchcock Michael J.M. (director) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, Biomea Fusion, Inc.
| 2024-09-30 | director | 10,000 0.029% | $10.06 | $100,600 | -31.88% | |||
| 2024-06-11 | Chief Financial Officer | 12,509 0.0348% | $4.43 | $55,361 | +46.39% | |||
| 2023-06-01 | Sale | 10 percent owner | 50,000 0.1638% | $34.56 | $1.73M | -57.40% | ||
| 2023-05-31 | Sale | 10 percent owner | 75,000 0.2524% | $33.81 | $2.54M | -55.18% | ||
| 2023-05-12 | Sale | 10 percent owner | 25,000 0.0841% | $33.84 | $846,000 | -53.60% | ||
| 2023-05-09 | Sale | 10 percent owner | 150,000 0.5185% | $34.50 | $5.18M | -53.17% | ||
| 2023-05-08 | Sale | 10 percent owner | 100,000 0.3445% | $33.99 | $3.4M | -52.59% | ||
| 2023-04-20 | Sale | 10 percent owner | 200,000 0.6723% | $29.12 | $5.82M | -43.70% | ||
| 2023-03-31 | Sale | 10 percent owner | 200,000 0.6812% | $31.25 | $6.25M | -45.44% | ||
| 2023-03-30 | 400,000 1.2695% | $30.00 | $12M | -47.04% | ||||
| 2022-11-14 | director | 5,000 0.0169% | $7.93 | $39,650 | +88.46% | |||
| 2022-11-11 | Chief Financial Officer | 4,100 0.0134% | $7.63 | $31,286 | +90.01% | |||
| 2022-08-16 | 30,684 0.1067% | $13.87 | $425,648 | -9.74% | ||||
| 2022-07-21 | Sale | 34,658 0.1118% | $11.21 | $388,516 | -2.11% | |||
| 2022-06-24 | Sale | 34,658 0.1168% | $11.76 | $407,578 | -5.69% | |||
| 2022-01-14 | Chief Financial Officer | 10,000 0.033% | $8.68 | $86,767 | -17.39% | |||
| 2021-09-17 | director | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | |||
| 2021-09-17 | 10 percent owner | 34,658 0.1193% | $10.96 | $379,852 | -20.13% | |||
| 2021-08-23 | President & COO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% | |||
| 2021-08-23 | CEO | 24,000 0.0831% | $13.20 | $316,872 | -32.89% |
Insider Historical Profitability
<0.0001%
| Valle Franco | Chief Financial Officer | 42500 0.1173% | $4.30 | 3 | 0 | +36.31% |
| Hitchcock Michael J.M. | director | 15000 0.0414% | $4.30 | 2 | 0 | +88.46% |
| Stergiopoulos Sotirios | director | 4400000 12.1417% | $4.30 | 1 | 0 | <0.0001% |
| Chen Bihua | 3570872 9.8538% | $4.30 | 2 | 0 | <0.0001% | |
| A2A Pharmaceuticals, Inc. | 10 percent owner | 3500000 9.6582% | $4.30 | 2 | 9 | <0.0001% |
| Erdtmann Rainer M | President & COO | 228470 0.6305% | $4.30 | 4 | 0 | <0.0001% |
| Butler Thomas Andrew | CEO | 228470 0.6305% | $4.30 | 4 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Fidelity Investments | $80.07M | 14.9 | 5.36M | 0% | +$0 | 0.01 | |
| State Street | $67.06M | 12.48 | 4.49M | +232.03% | +$46.86M | <0.01 | |
| Cormorant Asset Management Lp | $53.38M | 9.93 | 3.57M | 0% | +$0 | 2.49 | |
| Laurion Capital Management LP | $40.68M | 7.57 | 2.72M | -0.56% | -$229,990.80 | 0.29 | |
| Baker Bros Advisors LP | $31.53M | 5.87 | 2.11M | 0% | +$0 | 0.23 | |
| BlackRock | $29.5M | 5.49 | 1.97M | -8.48% | -$2.73M | <0.01 | |
| The Vanguard Group | $20.42M | 3.8 | 1.37M | +1.16% | +$233,608.70 | <0.0001 | |
| Janus Henderson | $19.21M | 3.58 | 1.29M | -25.2% | -$6.47M | 0.01 | |
| Driehaus Capital Management LLC | $17.85M | 3.32 | 1.19M | +0.95% | +$167,619.40 | 0.18 | |
| Aisling Capital Management LP | $11.94M | 2.22 | 798,757 | 0% | +$0 | 4.09 | |
| Geode Capital Management | $7.38M | 1.37 | 493,631 | +2.77% | +$199,003.97 | <0.01 | |
| Rafferty Asset Management Llc | $7.15M | 1.33 | 478,367 | +370.47% | +$5.63M | 0.02 | |
| Woodline Partners LP | $6.95M | 1.29 | 464,573 | 0% | +$0 | 0.06 | |
| Morgan Stanley | $6.84M | 1.27 | 457,421 | -4.39% | -$313,666.41 | <0.01 | |
| Citigroup | $6.12M | 1.14 | 409,558 | +669.95% | +$5.33M | 0.01 | |
| Goldman Sachs | $5.2M | 0.97 | 347,964 | +102.44% | +$2.63M | <0.01 | |
| Bank of America | $4.57M | 0.85 | 305,953 | +178.92% | +$2.93M | <0.0001 | |
| Susquehanna International Group | $4.3M | 0.8 | 287,864 | +233% | +$3.01M | <0.01 | |
| UBS | $3.95M | 0.74 | 264,199 | +260.38% | +$2.85M | <0.01 | |
| Northern Trust | $3.24M | 0.6 | 216,444 | -2.67% | -$88,623.60 | <0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $2.71M | 0.5 | 181,147 | 0% | +$0 | 0.07 | |
| Charles Schwab | $2.68M | 0.5 | 178,935 | +1.21% | +$31,963.10 | <0.01 | |
| T. Rowe Price | $2.66M | 0.49 | 177,602 | +0.58% | +$15,373.52 | <0.0001 | |
| Deutsche Bank | $2.57M | 0.48 | 171,763 | +0.19% | +$4,978.35 | <0.01 | |
| Wellington Management Company | $1.53M | 0.29 | 102,534 | +19.87% | +$254,120.22 | <0.0001 | |
| OZ MANAGEMENT LLC | $1.42M | 0.27 | 95,100 | New | +$1.42M | 0.02 | |
| Dimensional Fund Advisors | $1.34M | 0.25 | 89,865 | 0% | +$0 | <0.0001 | |
| Arrowmark Colorado Holdings Llc | $1.14M | 0.21 | 76,285 | 0% | +$0 | <0.01 | |
| Prosight Management Lp | $1.12M | 0.21 | 75,000 | +74.45% | +$478,534.55 | 0.31 | |
| Profund Advisors Llc | $1.09M | 0.2 | 72,877 | +340.96% | +$842,432.38 | 0.03 | |
| BNY Mellon | $955,563.00 | 0.18 | 63,917 | -10.31% | -$109,853.04 | <0.0001 | |
| Millennium Management LLC | $893,816.00 | 0.17 | 59,787 | -61.69% | -$1.44M | <0.01 | |
| Nuveen | $825,002.00 | 0.15 | 55,184 | 0% | +$0 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $814,312.00 | 0.15 | 54,469 | +69.68% | +$334,401.78 | <0.0001 | |
| Citadel Advisors LLC | $800,513.00 | 0.15 | 53,546 | New | +$800,513.00 | <0.0001 | |
| Wexford Capital, LLC | $706,821.00 | 0.13 | 47,279 | New | +$706,821.00 | 0.15 | |
| Barclays | $699,000.00 | 0.13 | 46,817 | -35.22% | -$379,995.49 | <0.0001 | |
| Swiss National Bank | $683,215.00 | 0.13 | 45,700 | 0% | +$0 | <0.0001 | |
| Marshall Wace | $636,452.00 | 0.12 | 42,572 | -82.23% | -$2.94M | <0.01 | |
| Nan Fung Group | $598,000.00 | 0.11 | 40,000 | 0% | +$0 | 0.65 | |
| Griffin Asset Management Inc | $566,455.00 | 0.11 | 37,890 | +39.35% | +$159,964.86 | 0.07 | |
| Jane Street Capital | $541,459.00 | 0.1 | 36,218 | -88.56% | -$4.19M | <0.01 | |
| Gsa Capital Partners Llp | $530,000.00 | 0.1 | 35,444 | -33.37% | -$265,418.69 | 0.04 | |
| Artia Global Partners Lp | $530,007.00 | 0.1 | 35,452 | +39.29% | +$149,499.89 | 0.13 | |
| Two Sigma | $499,345.00 | 0.09 | 33,401 | -75.84% | -$1.57M | <0.01 | |
| SG Americas Securities, LLC | $462,000.00 | 0.09 | 30,924 | New | +$462,000.00 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $459,683.00 | 0.09 | 30,748 | -15.28% | -$82,912.77 | <0.01 | |
| Afg Fiduciary Services Limited Partnership | $373,466.00 | 0.08 | 29,177 | New | +$373,466.00 | <0.01 | |
| AllianceBernstein | $435,643.00 | 0.08 | 29,140 | 0% | +$0 | <0.0001 | |
| RhumbLine Advisers | $418,083.00 | 0.08 | 27,966 | +2.22% | +$9,089.41 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.